Analysis of changes in PCSK9 and TNF-α concentrations in response to physical exercises using virtual reality in patients in the fifth stage of chronic kidney disease undergoing hemodialysis

BACKGROUND

The problem of reduced physical activity in patients with stage 5 Chronic Kidney Disease (CKD) is becoming more and more interesting in the medical community. One of the innovative solutions that can significantly increase patients' motivation to exercise is the integration of physical training with virtual reality (VR) technology during hemodialysis. The aim of this study was to comprehensively assess the impact of regular physical activity using virtual reality on the concentration of plasma PCSK9 protein and TNF-α in patients with stage 5 CKD treated with hemodialysis.

METHODS

A prototype of the NefroVR system was used in the research project. The study group consisted of patients who were entrusted with the task of conducting training using the prototype of the NefroVR system.

RESULTS

In the conducted research, a significant decrease in PCSK9 protein and TNF-α concentration was observed in the study group after 3 months of exercises using virtual reality in hemodialysis patients.

CONCLUSION

Regular physical activity using innovative physiotherapy methods, such as virtual reality, contributes to the improvement of inflammatory parameters and may improve lipid homeostasis.

CLINICAL TRIAL NUMBER

not applicable.

CLINICAL, INSTRUMENTAL AND BIOCHEMICAL ASSOCIATIONS OF THE DEGREE OF PHYSICAL RECOVERY IN PATIENTS SUFFERED FROM ACUTE CORONARY SYNDROME AT THE COMPLETION OF IN-HOSPITAL REHABILITATION PERIOD

OBJECTIVE

The aim: To determine the clinical, instrumental and biochemical factors associated with the degree of physical recovery in patients suffered from acute coronary syndrome (ACS) at the completion of in-hospital rehabilitation period.

PATIENTS AND METHODS

Materials and methods: We enrolled 88 patients (all were males); 77 patients had ACS/STEMI and 11 with ACS/unstable angina. The mean age was (median, interquartile range) was 58 (49-64) years. We analyzed clinical, laboratory (including the circulating proprotein convertase subtilisin/kexin type 9 (PSK9) level in blood serum), transthoracic echocardiography and (urgent or delayed) coronary angiography data. Symptom-limited exercise tolerance (ET) test was performed predominantly at the second week of in-hospital stay. According to ET-test results, patients were subdivided into the groups with low (G1; 43 [48,9 %]) and high ET (G2; n=45 [51,1 %]).

RESULTS

Results: G1 (vs. G2) was characterized by older age, lower estimated glomerular filtration rate (eGFR) and higher left atrial (LA) dimension. The cases of any left anterior descending artery (LAD) lesion were more frequent in G1 (25 % vs. 2 % in G2, respectively; p=0,004). We revealed a decrease in PSK9 level after ET-test (pre-ET vs. post-ET: 824,0 (371,0-1073,0) vs. 676,0 (441,9-995,9) ng/ml, respectively; p=0,004 [N=35]).

CONCLUSION

Conclusions: At the completion of in-hospital rehabilitation period, the insufficient physical recovery in patients suffered from ACS associated with older age, lower eGFR, higher LA dimension, and more frequent any LDA lesion cases. Physical exercises favored the decrease in PCSK9 levels in blood serum.

Physical activity to reduce PCSK9 levels

The amount of physical activity (PA) people practice everyday has been reducing in the last decades. Sedentary subjects tend to have an impaired lipid plasma profile with a higher risk of atherosclerosis and related cardio- and cerebrovascular events. Regular PA helps in both primary and secondary cardiovascular prevention because of its beneficial effect on the whole metabolism. Several studies reported lower levels of plasma lipids in trained subjects, but the precise mechanisms by which PA modulates lipoproteins remain only partially described. Thereupon, proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serin protease whose main function is to reduce the amount of low-density lipoprotein cholesterol (LDL-C) receptors, with the direct consequence of reducing LDL-C uptake by the liver and increasing its circulating pool. Accordingly, recently developed PCSK9 inhibitors improved cardiovascular prevention and are increasingly used to reach LDL-C goals in patients at high CV risk. Whether PA can modulate the levels of PCSK9 remains partially explored. Recent studies suggest PA as a negative modulator of such a deleterious CV mediator. Yet the level of evidence is limited. The aim of this review is to summarize the recent reports concerning the regulatory role of PA on PCSK9 plasma levels, highlighting the beneficial role of regular exercise on the prevention of atherosclerosis and overall CV health.